4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell MalignanciesPart 1:r/r B-cell Malignancies; Part 2:B-cell MalignanciesActive, not recruitingPhase 1 / Phase 22026-06-08NCT04014205
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast cancer, breast disorder, breast neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, metastatic malignant neoplasm, neoplasm, ovarian cancer, ovarian disorder, skin disorderRecruitingPhase 1 / Phase 22026-04-01NCT05735080
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmRecruitingPhase 12025-10-31NCT06549790
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET AlterationsNeoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasmRecruitingPhase 1 / Phase 22025-07-02NCT06669117